STOCK TITAN

Abbott Laboratories (ABT) director gets RSU and option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ABBOTT LABORATORIES director Michael O’Grady reported equity awards under the company’s 2026 Incentive Stock Program. He was granted 2,286 restricted stock units, each convertible into one Abbott common share upon separation from service, death, or a change in control as defined in the program.

He also received an option to buy 5,929 Abbott common shares at an exercise price of $91.86 per share, expiring on April 23, 2036, in a transaction exempt from Section 16 under Rule 16b-3. Following these awards, his direct holdings of Abbott common shares reported in this filing total 7,603 shares.

Positive

  • None.

Negative

  • None.
Insider O'Grady Michael
Role null
Type Security Shares Price Value
Grant/Award Option (right to buy) 5,929 $0.00 --
Grant/Award Common shares without par value 2,286 $0.00 --
Holdings After Transaction: Option (right to buy) — 5,929 shares (Direct, null); Common shares without par value — 7,603 shares (Direct, null)
Footnotes (1)
  1. Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3.
Restricted stock units granted 2,286 units Award under Abbott Laboratories 2026 Incentive Stock Program
Stock options granted 5,929 options Option (right to buy) Abbott common shares
Option exercise price $91.86 per share Conversion or exercise price for 5,929-share option grant
Option expiration date April 23, 2036 Expiration for stock option granted on April 24, 2026
Shares held after transaction 7,603 shares Total Abbott common shares directly held after awards
Section 16 exemption Rule 16b-3 Stock option grant exempt from Section 16 under Rule 16b-3
Restricted stock unit financial
"Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Incentive Stock Program financial
"granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program")"
change in control financial
"on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Section 16 regulatory
"Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
Rule 16b-3 regulatory
"Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
O'Grady Michael

(Last)(First)(Middle)
100 ABBOTT PARK ROAD

(Street)
ABBOTT PARK ILLINOIS 60064

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common shares without par value04/24/2026A2,286(1)A$07,603D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option (right to buy)(2)$91.8604/24/2026A5,92904/24/202604/23/2036Common Shares5,929$05,929D
Explanation of Responses:
1. Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
2. Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3.
/s/ Michael G. O'Grady by Jessica H. Paik, Attorney-in-Fact04/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Abbott Laboratories (ABT) director Michael O’Grady receive in this Form 4 filing?

Michael O’Grady received equity awards, not open-market trades. He was granted 2,286 restricted stock units and an option for 5,929 Abbott common shares under the 2026 Incentive Stock Program, reflecting routine director compensation rather than discretionary buying or selling.

How many restricted stock units did Michael O’Grady receive from Abbott Laboratories (ABT)?

Michael O’Grady was granted 2,286 restricted stock units. Each unit represents the right to receive one Abbott common share, payable on the earlier of his separation from service, death, or a qualifying change in control, as defined in Abbott’s 2026 Incentive Stock Program.

What are the key terms of Michael O’Grady’s Abbott (ABT) stock option grant?

He received an option for 5,929 Abbott common shares with an exercise price of $91.86 per share. The option was granted under Abbott’s 2026 Incentive Stock Program and expires on April 23, 2036, in a transaction exempt from Section 16 under Rule 16b-3.

When will Michael O’Grady’s Abbott (ABT) restricted stock units be paid out?

The 2,286 restricted stock units will be paid on a one-to-one basis in common shares on the earlier of O’Grady’s separation from service, his death, or a change in control, according to the terms of Abbott’s 2026 Incentive Stock Program.

How many Abbott (ABT) common shares does Michael O’Grady hold after these awards?

Following these transactions, Michael O’Grady’s Form 4 reports 7,603 Abbott common shares held directly. This figure reflects his direct ownership position after the grant of restricted stock units and the stock option award disclosed in the filing.

Were Michael O’Grady’s Abbott (ABT) equity awards open-market purchases or sales?

The transactions are grants under a company plan, not market trades. Both the restricted stock units and stock option were awarded under Abbott’s 2026 Incentive Stock Program and are classified as grant or award acquisitions exempt from Section 16 under Rule 16b-3.